Atogepant's Advantage in Chronic Migraine is Illustrated by Phase 3 PROGRESS Results.

Published Date: 04 May 2023

Atogepant 30 mg twice daily and 60 mg once daily reduced monthly migraine days more than placebo did, and a higher proportion of patients experienced a 50% or greater reduction in MMDs over the course of three months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot